Obstructive sleep apnea versus central sleep apnea: prognosis in systolic heart failure

Arild Hetland1,2, Maria Vistnes3, Kristina H Haugaa2,4

  • 1Department of Cardiology, The Hospital of Oestfold, Oestfold, Norway.

Insights

Cheyne-Stokes respiration (CSR) in chronic heart failure (CHF) patients is linked to higher mortality compared to obstructive sleep apnea (OSA). This study found CSR independently predicts worse outcomes in CHF patients.

Area of Science:

  • Cardiology
  • Sleep Medicine
  • Pulmonology

Background:

  • Obstructive sleep apnea (OSA) and Cheyne-Stokes respiration (CSR) are prevalent in chronic heart failure (CHF) and associated with increased mortality.
  • Differentiating the prognostic impact of CSR versus OSA in similar CHF patient cohorts is crucial for risk stratification.

Purpose of the Study:

  • To compare the prognostic significance of CSR against OSA in patients diagnosed with CHF.

Main Methods:

  • Sleep-disordered breathing (SDB) screening was performed on CHF patients (NYHA class II-IV, LVEF ≤45%).
  • Included were 43 patients with >25% CSR and 19 patients with OSA (AHI ≥6).
  • Patients were followed for a median of 1,371 days, with mortality and combined mortality/hospital admissions as endpoints.

Main Results:

  • CSR patients exhibited significantly higher mortality (53% vs. 26%) and combined endpoints (93% vs. 74%) compared to OSA patients.
  • CSR remained a significant independent predictor of mortality (HR, 4.73) after adjusting for confounding factors.
  • Hospital admission rates did not significantly differ between the CSR and OSA groups post-adjustment.

Conclusions:

  • In CHF patients, CSR is associated with significantly higher mortality than OSA, independent of age and cardiac function.
  • CSR serves as an independent predictor of poor prognosis in CHF patients.
  • Hospital admission rates were comparable between CSR and OSA groups after statistical adjustment.
Abstract

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.5K
Sleep Apnea01:21

Sleep Apnea

Sleep apnea is a condition where breathing stops intermittently during sleep, often leading to significant health issues. Each episode can last from 10 to 20 seconds or more and is frequently accompanied by a brief arousal from sleep. This disturbance, largely unnoticed by the individual, can lead to severe daytime fatigue. Commonly, individuals seek help after being informed by their partners about loud snoring and noticeable breathing pauses during sleep.
The condition is more prevalent among...
371
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
157
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
558
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
649
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
189